Wednesday, July 8, 2026

biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases

Nanjing Legend Biotech

Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Ca

2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
Clinical program

LCAR-B4822M CAR-T Cell Immunotherapy

Phase 1 · small molecule · Refractory or Relapsed Multiple Myeloma

LCAR-B4822M CAR-T Cell Immunotherapy for Refractory or Relapsed Multiple Myeloma is a Phase 1 program (small_molecule) at Nanjing Legend Biotech Co. with 1 ClinicalTrials.gov record(s).

← All Nanjing Legend Biotech Co. projects Phase 1 small molecule active

Internal code LCAR-B4822M

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1
Modality
small_molecule
Indication
Refractory or Relapsed Multiple Myeloma
Status
active
Trials
1